Skip to main content

Table 3 Cox regression analysis of the NV risk at any given age in patients with DMD

From: Influence of β2 adrenergic receptor genotype on risk of nocturnal ventilation in patients with Duchenne muscular dystrophy

 

β

SE

Wald

p-value

HR

95% CI

Genotype

1.87

0.71

2.66

< 0.05

6.52

1.64–25.99

Age (yrs)

−0.57

0.10

−5.55

< 0.05

0.57

0.46–0.69

Ambulatory Status

3.01

0.79

−3.84

< 0.05

0.05

0.01–0.23

Corticosteroid-use (yrs)

0.07

0.05

−1.44

0.15

0.93

0.84–1.03

Weight (cm)

0.02

0.01

2.29

< 0.05

1.02

1.00–1.04

FVC (L)

−1.80

0.45

−4.02

< 0.05

0.17

0.07–0.39

  1. SE standard error, HR hazard ratio, CI confidence interval, FVC forced vital capacity, Age: patient age at entry into the study; Arg16: patients who were homozygous or heterozygous for the β2-adrenergic receptor (ADRB2) resulting in at least one arginine substitution at amino acid 16 (n = 26); Gly16: patients who were homozygous for ADRB2 resulting in a glycine substitution at amino acid 16 (n = 147); genotype was coded as: 0 = Arg16, 1 = Gly16; ambulatory status was coded as: 0 = non-ambulatory, 1 = ambulatory; there was a significant influence of genotype, ambulatory status, weight, and FVC on risk of NV use